GADODIAMIDE vs IOHEXOL

Compare GADODIAMIDE (OMNISCAN) and IOHEXOL (Omnipaque) — clinical data, side effects, and patient experiences.

GADODIAMIDE

OMNISCAN · Diagnostic Agent

How it works

12.2 Pharmacodynamics In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These varia...

Approved for

spine

and associated tissues ( 1.1 ) Facilitate the visualization of lesions with abnormal vascularity within the thoracic

abdominal

pelvic cavities

IntravenousTablet

IOHEXOL

Omnipaque · Diagnostic Agent

How it works

12.1 Mechanism of Action The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohe...

Approved for

1 INDICATIONS AND USAGE OMNIPAQUE is a radiographic contrast agent indicated for intrathecal

intra-arterial

intravenous

oral

IntravenousTablet

Quick Comparison

GADODIAMIDEIOHEXOL

Drug Class

Diagnostic Agent

Route

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GADODIAMIDE

Anxiety

1-10%

Joint Pain

0.1-1%

Peripheral Edema

0.1-1%

Rash

0.1-1%

Weakness

0.1-1%

IOHEXOL

Itching

>10%

Shortness of Breath

>10%

Nausea

1-10%

Vomiting

1-10%

Rash

1-10%

Cough

0.1-1%

Low Blood Pressure

0.1-1%

Fever

0.1-1%

FDA Warnings

GADODIAMIDE

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Anaphylactoid and other serious hypersensitivity reactions including fatal reactions have occurred particularly in patients with history of allergy or drug reactions
1 Risk Associated with Intrathecal Use Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures
2 Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs
The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing

IOHEXOL

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Life-threatening or fatal reactions can occur
Minimize dose and maintain adequate hydration to minimize risk
5 ) Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age: Individualize thyroid function monitoring based on risk factors such as prematurity
1 Risks Associated with Intrathecal Administration of OMNIPAQUE Injection 140 mg Iodine/mL and 350 mg Iodine/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures [see Dosage and Administration (2

Clinical Trial Data

No head-to-head clinical studies found for GADODIAMIDE vs IOHEXOL.

GADODIAMIDE vs IOHEXOL: What You Should Know

Key Differences

Both GADODIAMIDE and IOHEXOL belong to the Diagnostic Agent class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

GADODIAMIDE carries 4 FDA warnings. IOHEXOL carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

GADOBUTROL vs IOHEXOL→GADOBUTROL vs GADODIAMIDE→AIR 90% CARBON DIOXIDE 10% vs IOHEXOL→AIR 90% CARBON DIOXIDE 10% vs GADODIAMIDE→IOHEXOL vs IOPAMIDOL→GADODIAMIDE vs IOPAMIDOL→

Loading comparison data...

GADODIAMIDE vs IOHEXOL

Compare GADODIAMIDE (OMNISCAN) and IOHEXOL (Omnipaque) — clinical data, side effects, and patient experiences.

GADODIAMIDE

OMNISCAN · Diagnostic Agent

How it works

12.2 Pharmacodynamics In magnetic resonance imaging, visualization of normal and pathologic tissue depends in part on variations in the radiofrequency signal intensity. These varia...

Approved for

spine

and associated tissues ( 1.1 ) Facilitate the visualization of lesions with abnormal vascularity within the thoracic

abdominal

pelvic cavities

IntravenousTablet

IOHEXOL

Omnipaque · Diagnostic Agent

How it works

12.1 Mechanism of Action The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohe...

Approved for

1 INDICATIONS AND USAGE OMNIPAQUE is a radiographic contrast agent indicated for intrathecal

intra-arterial

intravenous

oral

IntravenousTablet

Quick Comparison

GADODIAMIDEIOHEXOL

Drug Class

Diagnostic Agent

Route

Intravenous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

GADODIAMIDE

Anxiety

1-10%

Joint Pain

0.1-1%

Peripheral Edema

0.1-1%

Rash

0.1-1%

Weakness

0.1-1%

IOHEXOL

Itching

>10%

Shortness of Breath

>10%

Nausea

1-10%

Vomiting

1-10%

Rash

1-10%

Cough

0.1-1%

Low Blood Pressure

0.1-1%

Fever

0.1-1%

FDA Warnings

GADODIAMIDE

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Anaphylactoid and other serious hypersensitivity reactions including fatal reactions have occurred particularly in patients with history of allergy or drug reactions
1 Risk Associated with Intrathecal Use Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures
2 Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs
The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing

IOHEXOL

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Life-threatening or fatal reactions can occur
Minimize dose and maintain adequate hydration to minimize risk
5 ) Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age: Individualize thyroid function monitoring based on risk factors such as prematurity
1 Risks Associated with Intrathecal Administration of OMNIPAQUE Injection 140 mg Iodine/mL and 350 mg Iodine/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures [see Dosage and Administration (2

Clinical Trial Data

No head-to-head clinical studies found for GADODIAMIDE vs IOHEXOL.

GADODIAMIDE vs IOHEXOL: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.